Remarkable Clarity

in the diagnosis and treatment of brain disorders through advanced imaging biomarkers

ADM Diagnostics, Inc. Announces Receipt of 510(k) FDA Clearance for its CorInsights® MRI Product

December 14, 2021

ADMdx Co-Publishes Results of the Effects of Riluzole in Patients With Alzheimer’s Disease

December 15, 2021

ADMdx Authors Chapter in New Book on the Alzheimer’s Drug Development Ecosystem

March 31, 2022

ADMdx Awarded New Patent Supporting Disease Diagnosis Using Pattern Analysis

June 28, 2022

ADM Diagnostics, Inc. Awarded $1.96 Million Grant From the National Institutes of Health

September 20, 2022

QIBA Amyloid PET Working Group Co-Chaired by ADMdx CEO Publishes Results

September 25, 2022

Tau PET Profile Group Formed by QIBA

October 15, 2022

Results of ADMdx’s Visual Read of MK-6240 Tau PET scans Published

February 12, 2023

ADMdx Presents at SNMMI 

June 27, 2023

ADMdx has been awarded funds for the second year of our SBIR Phase II Grant from the National Institutes of Aging

July 31, 2023

Dawn Matthews to speak at the Alzheimer’s Drug Discovery Foundation Therapeutic Investigator Day

September 15, 2023

Defining clarity in diagnostics

At ADMdx, we’re applying advances in image measurement, analysis, and AI to support earlier, more accurate identification of brain disorders, including Alzheimer’s disease and other dementias.

CorInsights^® MRI, our first FDA 510k cleared product, is powered by ADMdx technology. This advanced reporting tool uses readily available MRI brain scans to support medical professionals in providing a new standard of care.

Learn more about CorInsights® MRI

Enabling success in clinical trials

ADMdx provides a full spectrum of imaging CRO services for CNS imaging trials using PET and MRI biomarkers, including:

Protocol input, charter and technical manual development
Imaging site identification and qualification
Central data receipt and quality control
Radiology reads
Advanced image processing and analysis
Reporting
Data management and archival

We support clinical trial success by combining key elements of CLARITY, QUALITY, PARTNER FOCUS, and INSIGHT.

Using our reference database and multivariate image classification, we address critical questions to support trial success:

Patient inclusion based upon:
- Disease patterns
- Pathology
Patient stratification for analysis, by predicting:
- Rates of clinical decline
- Pathology accumulation rates
Detection of treatment effect
Treatment responder characteristics

Learn more about our clinical trial capabilities.

Harnessing the power of imaging for UNPARALLELED INSIGHTS

Using our reference database of tens of thousands of PET and MRI scans with associated clinical and fluid biomarker data and through long-standing collaborations with thought leaders from major institutions, ADMdx has characterized the effects of diseases and syndromes, including:

Alzheimer’s disease progression from amyloid-negative controls through amyloid and tau-positive AD dementia
Atypical Alzheimer’s disease variants, including Posterior Cortical Atrophy, amyloid-positive Corticobasal Syndrome, and amyloid positive Logopenic Progressive Aphasia, and Early Onset Alzheimer’s Disease
Frontotemporal dementia variants, including behavioral, semantic dementia, primary progressive aphasia, and nonfluent progressive aphasia
Traumatic brain injury
Parkinson’s disease
White matter / cerebrovascular disease
Down Syndrome

Join us for ongoing updates, including webinar sessions, group calls, user experience surveys and more.